ReviewAnnals of the New York Academy of Sciences2016
Sulfur mustard inhalation: mechanisms of injury, alteration of coagulation, and fibrinolytic therapy.
Review in Annals of the New York Academy of Sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Cannabinoid-2 Receptor Activation Attenuates Sulfur Mustard Analog 2-Chloroethyl-Ethyl-Sulfide-Induced Acute Lung Injury in Mice.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Expressions of apoptotic protein and gene following sulfur mustard-induced acute pulmonary injuries in rats.Iranian journal of basic medical sciences · 2025Article
- A point of care sensor for detection of alcohols, aldehydes and esters in urinary metabolites of war veterans injured by sulfur mustard.RSC advances · 2024Article
- Mesna Improves Outcomes of Sulfur Mustard Inhalation Toxicity in an Acute Rat Model.The Journal of pharmacology and experimental therapeutics · 2024Article
- Countermeasures against Pulmonary Threat Agents.The Journal of pharmacology and experimental therapeutics · 2024Review
- Respiratory function after 30+ years following sulfur mustard exposure in survivors in Sweden.Frontiers in medicine · 2024Article
- A computational approach for the identification of key genes and biological pathways of chronic lung diseases: a systems biology approach.BMC medical genomics · 2023Article
- Remifentanil modulates the TLR4‑mediated MMP‑9/TIMP1 balance and NF‑κB/STAT3 signaling in LPS‑induced A549 cells.Experimental and therapeutic medicine · 2023Article
- A review of chemical warfare agents linked to respiratory and neurological effects experienced in Gulf War Illness.Inhalation toxicology · 2022Review
- Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation.Frontiers in genome editing · 2022Article
- MicroRNA-mediated inflammation and coagulation effects in rats exposed to an inhaled analog of sulfur mustard.Annals of the New York Academy of Sciences · 2020Article
- Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review.Research and practice in thrombosis and haemostasis · 2020Review
- Extracellular nucleic acid scavenging rescues rats from sulfur mustard analog-induced lung injury and mortality.Archives of toxicology · 2020Article
- Therapeutic options to treat mustard gas poisoning - Review.Caspian journal of internal medicine · 2019Review
- Health perspectives among Halabja's civilian survivors of sulfur mustard exposure with respiratory symptoms-A qualitative study.PloS one · 2019Article
- Phosgene oxime: Injury and associated mechanisms compared to vesicating agents sulfur mustard and lewisite.Toxicology letters · 2018Review
- From the Cover: ImpairedProliferation and Differentiation of the Conducting Airway Epithelium Associated With Bronchiolitis Obliterans After Sulfur Mustard Inhalation Injury in Rats.Toxicological sciences : an official journal of the Society of Toxicology · 2017Article
- An Official American Thoracic Society Workshop Report: Chemical Inhalational Disasters. Biology of Lung Injury, Development of Novel Therapeutics, and Medical Preparedness.Annals of the American Thoracic Society · 2017Article
- A novel sulfur mustard (HD) vapor inhalation exposure model of pulmonary toxicity for the efficacy evaluation of candidate medical countermeasures.Inhalation toxicologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Acute lung injury due to sulfur mustard (SM) inhalation causes the formation of airway fibrin casts that obstruct airways at multiple levels, leading to acute respiratory failure and death. These pathophysiological effects are seen in rodent models of acute SM vapor inhalation, as well as in human victims of acute SM inhalation. In rat models, the initial steps in activation of the coagulation system at extravascular sites depend on tissue factor (TF) expression by airway cells, especially in the microparticle fraction, and these effects can be inhibited by TF pathway inhibitor protein. Not only does the procoagulant environment of the acutely injured lung contribute to airway cast formation, but these lesions persist in airways because of the activation of multiple antifibrinolytic pathways, including plasminogen activator inhibitor-1, thrombin-activatable fibrinolysis inhibitor, and α2-antiplasmin. Airway administration of tissue plasminogen activator can overwhelm these effects and save lives by preventing fibrin-dependent airway obstruction, gas-exchange abnormalities, and respiratory failure. In human survivors of SM inhalation, fibrotic processes, including bronchiolitis obliterans and interstitial fibrosis of the lung, are among the most disabling chronic lesions. Antifibrotic therapies may prove useful in preventing either or both of these forms of chronic lung damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.